Introduction: Neuroendocrine tumors (NET) constitute a heterogenous group of neoplasms. The development of Gallium-68-labeled somatostatin analogues, such as DOTA-NOC or DOTA-TOC, PET/CT have dramatically improved the diagnosis of neuroendocrine tumors. Surgery remains the treatment of choice for localized disease as well as metastatic disease. The aims of surgery are: improvement of symptoms, reduction of tumor mass / burden and to give better quality of life to patients. Recurrent laparotomies often lead to multiple adhesions and altered anatomy. So it is increasingly difficult for imaging physicians and surgeons to separate non-malignant from malignant tissue.
Aim(s): We investigated the intraoperative use of Ga-68 labeled somatostatin analogues in patients with advanced neuroendocrine tumors.
Materials and methods: Six patients (M:F 4:2; mean age 57.5 years) with advanced neuroendocrine tumors were advised for operation using Gallium-68-labeled somastostatin analogues intraoperativly with Gamma-detection. Mean application: 260 MBq 68Ga-DOTA-TOC/TATE 1.5 hours preoperatively.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Dr. Daniel Kaemmerer
To read results and conclusion, please login ...
Further abstracts you may be interested in